Edward J. Ludwig Sells 12,000 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) Director Edward J. Ludwig sold 12,000 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the transaction, the director now directly owns 24,398 shares of the company’s stock, valued at approximately $2,573,501.04. The trade was a 32.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Boston Scientific Trading Down 0.2 %

NYSE BSX opened at $105.80 on Thursday. The firm’s 50 day moving average price is $95.50 and its two-hundred day moving average price is $87.72. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a twelve month low of $64.54 and a twelve month high of $107.17. The stock has a market cap of $155.93 billion, a price-to-earnings ratio of 84.64, a PEG ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Equities analysts anticipate that Boston Scientific Co. will post 2.83 EPS for the current year.

Hedge Funds Weigh In On Boston Scientific

A number of large investors have recently made changes to their positions in the business. Thurston Springer Miller Herd & Titak Inc. increased its stake in Boston Scientific by 32.4% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,786 shares of the medical equipment provider’s stock valued at $317,000 after buying an additional 927 shares during the period. ORG Wealth Partners LLC purchased a new position in shares of Boston Scientific during the 3rd quarter valued at $89,000. Grove Bank & Trust increased its stake in shares of Boston Scientific by 12.9% in the third quarter. Grove Bank & Trust now owns 2,801 shares of the medical equipment provider’s stock worth $235,000 after acquiring an additional 320 shares during the last quarter. Creative Planning raised its holdings in shares of Boston Scientific by 7.7% during the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock worth $17,113,000 after acquiring an additional 14,663 shares in the last quarter. Finally, Boomfish Wealth Group LLC acquired a new stake in Boston Scientific during the third quarter valued at $281,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus increased their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Citigroup increased their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Raymond James boosted their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Royal Bank of Canada increased their price target on Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research note on Thursday, February 6th. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average price target of $107.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.